Effective immediately, Princeton-based Bristol Myers Squibb has appointed Cari Gallman as executive vice president, general counsel and chief policy officer. Gallman succeeds Sandra (Sandy) Leung, who has chosen to retire after an extraordinary 33-year career at the company. Gallman has held leadership positions at Bristol Myers Squibb for 10 years, most recently serving as executive vice president, corporate affairs.
Gallman, an accomplished leader with extensive experience in pharmaceutical law and compliance, will lead the law department, which includes intellectual property, commercial and regulatory law, litigation, securities and corporate governance, transactions, corporate security and compliance and ethics, as well as global and U.S. policy and government affairs.
“Cari brings a unique combination of legal, policy and communications expertise, coupled with an impressive ability to inspire teams, uphold ethical business practices and champion patient voices,” Christopher Boerner, board chair and chief executive officer, Bristol Myers Squibb said. “I am confident that under Cari’s leadership, our legal and policy teams are well positioned to advance Bristol Myers Squibb’s efforts to drive and deliver innovation to patients facing serious diseases.”
“It is an honor to have the opportunity to lead the incredible teams that govern and counsel Bristol Myers Squibb in advancing its mission to deliver transformational medicines to more patients,” Gallman said. “I am committed to continuing to build on the company’s culture of integrity and shape a dynamic policy environment that protects innovation and patients.”
